Ronald Ernest Kates Sign in to save

ORCID 0000-0003-3550-1051 OpenAlex profile details not fetched

–

Citations

–

h-index

–

i10-index

–

Works (all)

Aachen papers

Departments & institutes in Aachen

No department could be parsed from this author's affiliation strings.

Affiliations exactly as printed on papers (6)

3× West German Study Group, Moenchengladbach, Germany
2× West German Study Group, Mönchengladbach, Germany;
1× West German Study Group, Moenchengladbach, Germany;
1× West German Study Group GmbH, Moenchengladabach, Germany
1× 1West German Study Group, Moenchengladbach, Germany
1× 21West German Study Group, Moenchengladbach, Germany

Papers 9 stored

All · Aachen affiliation only

Data from Impact of RNA Signatures on pCR and Survival after 12-Week Neoadjuvant Pertuzumab plus Trastuzumab with or without Paclitaxel in the WSG-ADAPT HER2+/HR− Trial
2023 other Biochemistry, Genetics and Molecular Biology Breast Cancer Treatment Studies Open access

0

citations
Impact of RNA Signatures on pCR and Survival after 12-Week Neoadjuvant Pertuzumab plus Trastuzumab with or without Paclitaxel in the WSG-ADAPT HER2+/HR− Trial
2022 Clinical Cancer Research article Biochemistry, Genetics and Molecular Biology Breast Cancer Treatment Studies Open access

14

citations
Concordance and clinical impact of ER, PR, HER2 expression by local and central immunohistochemistry versus RT-PCR in HR+/HER2- early breast cancer (EBC): Results from the ADAPT trial.
2022 Journal of Clinical Oncology conference-abstract Biochemistry, Genetics and Molecular Biology Breast Cancer Treatment Studies

1

citations
De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR–): survival outcomes from a multicentre, open-label, randomised, phase 2 trial
2022 The Lancet Oncology article Medicine HER2/EGFR in Cancer Research

93

citations
Corrigendum to “De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR− phase II trial: efficacy, safety, and predictive markers for 12weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxel”
2022 Annals of Oncology erratum Medicine HER2/EGFR in Cancer Research Open access

1

citations
De-escalated neoadjuvant pertuzumab+trastuzumab with or without paclitaxel weekly in HR-/HER2+ early breast cancer: ADAPT-HR-/HER2+ biomarker and survival results.
2021 Journal of Clinical Oncology conference-abstract Medicine HER2/EGFR in Cancer Research

21

citations
Abstract GS4-04: Endocrine therapy alone in patients with intermediate or high-risk luminal early breast cancer (0-3 lymph nodes), Recurrence Score <26 and Ki67 response after preoperative endocrine therapy: Primary outcome results from the WSG-ADAPT HR+/HER2- trial
2021 Cancer Research conference-abstract Biochemistry, Genetics and Molecular Biology Breast Cancer Treatment Studies

12

citations
ADAPTcycle: Adjuvant dynamic marker-adjusted personalized therapy (ADAPT) comparing endocrine therapy plus ribociclib versus chemotherapy in intermediate-risk HR+/HER2- early breast cancer (EBC).
2020 Journal of Clinical Oncology conference-abstract Medicine Advanced Breast Cancer Therapies

18

citations
The run-in phase of the prospective WSG-ADAPT HR+/HER2– trial demonstrates the feasibility of a study design combining static and dynamic biomarker assessments for individualized therapy in early breast cancer
2020 Therapeutic Advances in Medical Oncology article Biochemistry, Genetics and Molecular Biology Breast Cancer Treatment Studies Open access

46

citations

9 results

Ronald Ernest Kates ▲ Sign in to save

Departments & institutes in Aachen

Papers 9 stored

Ronald Ernest Kates Sign in to save